Pyridostigmine for treatment of neurogenic orthostatic hypertension

Abstract
We report the result of a follow-up, open-label study of pyridostigmine for treatment of orthostatic hypotension. Aim of the study was to evaluate self-reported efficacy and patients' satisfaction with the medication. Most patients were very satisfied with the medication and chose to continue it.